Novartis psoriasis drug maintains efficacy after four years: study

ZURICH (Reuters) – Novartis’s psoriasis drug Cosentyx showed long-term efficacy in keeping patients’ skin clear, the Swiss drugmaker said on Saturday, citing a study it hopes will ultimately help the company to win business from rival medicines made by Amgen and Johnson & Johnson.

Source: Reuters Health